Poxel SA, the France-based dynamic biopharmaceutical firm developing advanced drugs for metabolic diseases, has reportedly announced the preclinical outcomes for PXL770, the main molecule in its AMPK (adenosine monophosphate-activated protein kinase) platform.

Reportedly, the molecule was assessed in a rodent non-alcoholic steatohepatitis (NASH) model together with other main agents in development, including obeticholic acid (FXR agonist), semaglutide (GLP-1 receptor agonist), and MGL-3196 (thyroid receptor β agonist).

According to sources familiar with the knowledge of the matter, outcomes showed the potential of PXL770 as new NASH therapy that may produce additional benefits when combined with other agents with different mechanisms of action.

Apparently, PXL770 was also assessed in rodent models of DKD (Diabetic Kidney Disease) which also evaluated cardiac dysfunction and ALD (adrenoleukodystrophy / AMN (adrenomyeloneuropathy), a fatal disease characterized by neurodegeneration. These results showed that AMPK activation possibly leads to broader usefulness for other diseases mediated by metabolic pathway dysfunction.

Sources cite that the company conducted these clinical trials to further investigate applications of PXL770 in numerous metabolic diseases. Moreover, all  these clinical trials are in support of Phase 2 clinical study and NASH development program.

Speaking on which, David E. Moller, MD, CSO at Poxel said that AMPK is a convincing pharmaceutical target that has been detected to modulate both inflammatory and metabolic pathways and has the potential to treat numerous rare metabolic and chronic diseases.

Mr. Moller added that new preclinical data indicate the potential of PXL770 to show even better additive or synergistic benefits to treat the main causes of NASH in combination with other agents in development. The company is rather delighted at these new findings indicating the potential of PXL770 and AMPK activation for treating other chronic disorders ranging from most common to uncommon monogenic metabolic disorders, Mr. Moller said.
 

Source Credit - https://www.poxelpharma.com/en_us/news-media/press-releases/detail/152/poxel-announces-program-update-and-preclinical-results-on